Applicant: Tsann-Long Su et al. Serial No.: 10/799,576

Filed : March 12, 2004

Page : 2 of 19

## Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application.

## Listing of Claims:

1. (Currently amended) A compound having formula (I):

wherein,

each of  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$ ,  $R_6$ ,  $R_7$ ,  $R_8$ ,  $R_9$ ,  $R_{10}$ ,  $R_{11}$ ,  $R_{12}$ , and  $R_{13}$  is, independently, hydrogen, halo, nitro, hydroxyl,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $C_1$ - $C_6$  hydroxyalkyl, CONHR<sup>a</sup>, NR<sup>b</sup>R<sup>c</sup>, CONH(CH<sub>2</sub>)<sub>m</sub>NR<sup>b</sup>R<sup>c</sup>, L-N(CH<sub>2</sub>CH<sub>2</sub>Cl)<sub>2</sub>, or a DNA minor groove binder;

L is  $(CH_2)_p$  or  $O(CH_2)_q$ ;

m is 1, 2, 3, or 4;

p is 0, 1, 2, 3, or 4;

q is 1, 2, 3, 4, 5, 6, 7, or 8;

in which,  $R^a$  is  $C_1$ - $C_6$  alkyl; each of  $R^b$  and  $R^c$  is, independently, hydrogen,  $C_1$ - $C_6$  alkyl,  $COR^d$ , or  $COOR^d$ ;  $R^d$  is  $C_1$ - $C_6$  alkyl,  $C_6$ - $C_{10}$  aryl, or  $C_7$ - $C_{12}$  aralkyl; and provided that at least one of  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$ ,  $R_6$ ,  $R_7$ ,  $R_8$ ,  $R_9$ ,  $R_{10}$ ,  $R_{11}$ ,  $R_{12}$ , and  $R_{13}$  is L-N(CH<sub>2</sub>CH<sub>2</sub>Cl)<sub>2</sub>, or a salt thereof.

Applicant: Tsann-Long Su et al. Attorney's Docket No.: 08919-0118001

Serial No.: 10/799,576 Filed: March 12, 2004

Page : 3 of 19

2. (Original) The compound of claim 1, wherein L is (CH<sub>2</sub>)<sub>p</sub>.

- 3. (Original) The compound of claim 2, wherein p is 0 or 1.
- 4. (Original) The compound of claim 1, wherein L is O(CH2)q.
- 5. (Original) The compound of claim 4, wherein q is 2 or 4.
- 6. (Original) The compound of claim 1, wherein one of  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ , or  $R_5$  is L-N(CH<sub>2</sub>CH<sub>2</sub>Cl)<sub>2</sub>.
  - 7. (Original) The compound of claim 6, wherein R2 or R3 is L-N(CH2CH2Cl)2.
  - 8. (Original) The compound of claim 7, wherein R2 is L-N(CH2CH2Cl)2.
  - 9. (Original) The compound of claim 8, wherein L is (CH<sub>2</sub>)<sub>p</sub>.
  - 10. (Original) The compound of claim 9, wherein p is 0 or 1.
  - 11. (Original) The compound of claim 8, wherein L is -O(CH<sub>2</sub>)<sub>q</sub>-.
  - 12. (Original) The compound of claim 11, wherein q is 2 or 4.
- (Original) The compound of claim 8, wherein each of R₁, R₃, R₄, and R₃ is, independently, hydrogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, or C₁-C₆ hydroxyalkyl.
  - 14. (Original) The compound of claim 13, wherein R<sub>4</sub> is C<sub>1</sub>-C<sub>6</sub> hydroxyalkyl.

Attorney's Docket No.: 08919-0118001

Applicant: Tsann-Long Su et al. Serial No.: 10/799,576 Filed: March 12, 2004

Page : 4 of 19

15. (Original) The compound of claim 14, wherein R<sub>4</sub> is CH<sub>2</sub>OH.

- (Original) The compound of claim 13, wherein each of R<sub>1</sub>, R<sub>3</sub>, R<sub>4</sub>, and R<sub>5</sub> is hydrogen.
  - 17. (Original) The compound of claim 7, wherein R<sub>3</sub> is L-N(CH<sub>2</sub>CH<sub>2</sub>Cl)<sub>2</sub>.
  - 18. (Original) The compound of claim 17, wherein L is (CH<sub>2</sub>)<sub>p</sub>.
  - 19. (Original) The compound of claim 18, wherein p is 0 or 1.
  - 20. (Original) The compound of claim 17, wherein L is -O(CH2)q-.
  - 21. (Original) The compound of claim 20, wherein q is 2 or 4.
- 22. (Original) The compound of claim 17, wherein each of R<sub>1</sub>, R<sub>2</sub>, R<sub>4</sub>, and R<sub>5</sub> is, independently, hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, or C<sub>1</sub>-C<sub>6</sub> hydroxyalkyl.
- 23. (Original) The compound of claim 21, wherein each of  $R_1,\,R_2,\,R_4,$  and  $R_5$  is hydrogen.
- 24. (Original) The compound of claim 6, wherein each of  $R_6$ ,  $R_7$ ,  $R_8$ ,  $R_9$ ,  $R_{10}$ ,  $R_{11}$ ,  $R_{12}$ , and  $R_{13}$  is, independently, hydrogen, halo, nitro,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy, CONHR<sup>a</sup>, CONH(CH<sub>2</sub>)<sub>m</sub>NR<sup>b</sup>R<sup>c</sup>, L-N(CH<sub>2</sub>CH<sub>2</sub>CI)<sub>2</sub>, or a DNA minor groove binder.
- 25. (Original) The compound of claim 24, wherein each of  $R_6$ ,  $R_7$ ,  $R_8$ ,  $R_9$ ,  $R_{10}$ ,  $R_{11}$ ,  $R_{12}$ , and  $R_{13}$  is, independently, hydrogen,  $C_1$ - $C_6$  alkyl, CONH(CH<sub>2</sub>)<sub>m</sub>NR<sup>b</sup>R<sup>c</sup>, L-N(CH<sub>2</sub>CH<sub>2</sub>Cl)<sub>2</sub>, or a DNA minor groove binder.

Applicant: Tsann-Long Su et al. Attorney's Docket No.: 08919-0118001

Serial No. : 10/799,576 Filed : March 12, 2004

Page : 5 of 19

26. (Original) The compound of claim 25, wherein one of R<sub>9</sub> and R<sub>10</sub> is CONH(CH<sub>2</sub>)<sub>m</sub>NR<sup>b</sup>R<sup>c</sup>, L-N(CH<sub>2</sub>CH<sub>2</sub>Cl)<sub>2</sub>, or a DNA minor groove binder, and the other is C<sub>1</sub>-C<sub>6</sub> alkyl or hydrogen.

- $\label{eq:constraint} 27. \ (Original) \ The \ compound \ of \ claim \ 26, \ wherein \ one \ of \ R_9 \ and \ R_{10} \ is \\ CONH(CH_2)_m NR^b R^c \ and \ the \ other \ is \ C_1-C_6 \ alkyl \ or \ hydrogen.$
- 28. (Original) The compound of claim 27, wherein one of  $R_9$  and  $R_{10}$  is  $CONH(CH_2)_2N(CH_3)_2$  and the other is  $CH_3$  or hydrogen.
- 29. (Original) The compound of claim 26, wherein one of  $R_9$  and  $R_{10}$  is L-N(CH<sub>2</sub>CH<sub>2</sub>Cl)<sub>2</sub> and the other is C<sub>1</sub>-C<sub>6</sub> alkyl or hydrogen.
- 30. (Original) The compound of claim 29, wherein one of  $R_9$  and  $R_{10}$  is  $N(CH_2CH_2Cl)_2$  or  $CH_3N(CH_2CH_2Cl)_2$  and the other is  $CH_3$  or hydrogen.
- (Original) The compound of claim 29, wherein one of R<sub>2</sub> and R<sub>10</sub> is
  O(CH<sub>2</sub>)<sub>2</sub>N(CH<sub>2</sub>CH<sub>2</sub>Cl)<sub>2</sub> or O(CH<sub>2</sub>)<sub>4</sub>N(CH<sub>2</sub>CH<sub>2</sub>Cl)<sub>2</sub> and the other is CH<sub>3</sub> or hydrogen.
- 32. (Original) The compound of claim 26, wherein one of  $R_9$  and  $R_{10}$  is a DNA minor groove binder and the other is  $C_1$ - $C_6$  alkyl or hydrogen.
- 33. (Original) The compound of claim 32, wherein one of R<sub>9</sub> and R<sub>10</sub> is CONH(CH<sub>2</sub>),r-J-W-(CH<sub>2</sub>),R<sup>e</sup> and the other is CH<sub>3</sub> or hydrogen; wherein r is 1, 2, 3, 4, or 5; t is 1, 2, 3, or 4, 5, or 6; J is -CONH- or -NHCO-; W is:

Applicant: Tsann-Long Su et al. Serial No.: 10/799,576

Filed : March 12, 2004

Page : 6 of 19

in which s is 0, 1, 2, 3, or 4,; each of X and Y is, independently, N or  $CR^f$  and W is  $NR^g$ , O, or S;  $R^e$  is  $NR^bR^e$ , NHCHO, or NHC(=NH)NH<sub>2</sub>; each of  $R^b$  and  $R^e$  is, independently, hydrogen,  $C_{1^c}C_6$  alkyl,  $COR^d$ , or  $COOR^d$ ; and each of  $R^f$  and  $R^g$  is, independently, hydrogen or  $C_{1^c}C_6$  alkyl.

- 34. (Original) The compound of claim 33, wherein s is 0, each of X and Y is CH, and W is NCH<sub>3</sub>.
  - 35. (Original) The compound of claim 34, wherein one of R<sub>9</sub> and R<sub>10</sub> is:

- 36. (Original) The compound of claim 35, wherein r and t are both 3, and  $R^e$  is N(CH<sub>3</sub>)<sub>2</sub>, NHCHO, or NHC(=NH)NH<sub>2</sub>.
  - 37. (Original) The compound of claim 34, wherein one of R<sub>9</sub> and R<sub>10</sub> is:

Attorney's Docket No.: 08919-0118001

Applicant: Tsann-Long Su et al. Serial No.: 10/799,576 Filed: March 12, 2004

Page : 7 of 19

- 38. (Original) The compound of claim 36, wherein r and t are both 3, and R° is N(CH<sub>3</sub>)<sub>2</sub>, NHCHO, or NHC(=NH)NH<sub>2</sub>.
- 39. (Original) The compound of claim 24, wherein each of  $R_6$ ,  $R_7$ ,  $R_8$ ,  $R_9$ ,  $R_{10}$ ,  $R_{11}$ ,  $R_{12}$ , and  $R_{13}$  is hydrogen.
- 40. (Original) The compound of claim 1, wherein one of  $R_6$ ,  $R_7$ ,  $R_8$ ,  $R_9$ ,  $R_{10}$ ,  $R_{11}$ ,  $R_{12}$ , and  $R_{13}$  is L-N(CH<sub>2</sub>CH<sub>2</sub>Cl)<sub>2</sub>.
  - 41. (Original) The compound of claim 40, wherein R9 is L-N(CH2CH2Cl)2.
  - 42. (Original) The compound of claim 41, wherein L is (CH<sub>2</sub>)<sub>p</sub>.
  - 43. (Original) The compound of claim 42, wherein p is 0 or 1.
  - 44. (Original) The compound of claim 41, wherein L is -O(CH<sub>2</sub>)<sub>0</sub>-.
  - 45. (Original) The compound of claim 44, wherein q is 2 or 4.
- 46. (Currently amended) The compound of claim 41, wherein each of R<sub>6</sub>, R<sub>7</sub>, R<sub>8</sub>, R<sub>10</sub>, R<sub>11</sub>, R<sub>12</sub>, and R<sub>13</sub> is, independently, hydrogen, halo, nitro, hydroxyl, C<sub>1</sub>-C<sub>6</sub> alkyl, or C<sub>1</sub>-C<sub>6</sub> alkoxy.

Applicant: Tsann-Long Su et al. Attorney's Docket No.: 08919-0118001

Serial No.: 10/799,576 Filed: March 12, 2004

Page : 8 of 19

47. (Currently amended) The compound of claim 40, wherein each of R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, or R<sub>5</sub> is, independently, hydrogen, hydroxyl, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>1</sub>-C<sub>6</sub> hydroxyalkyl, or NR<sup>5</sup>R<sup>6</sup>.

- 48. (Currently amended) The compound of claim 47, wherein  $R_2$  is hydroxyl or  $NR^bR^c$  and  $R_4$  is  $C_1$ - $C_6$  hydroxyalkyl.
  - 49. (Original) The compound of claim 48, wherein R2 is NH2 or NHCOOCH2CH3.
  - 50. (Original) The compound of claim 48, wherein R<sub>4</sub> is CH<sub>2</sub>OH.
  - 51. (Currently amended) The compound of claim 1, wherein the compound is:

Applicant: Tsann-Long Su et al. Serial No.: 10/799,576 Filed: March 12, 2004

Page : 9 of 19

Applicant: Tsann-Long Su et al.

Serial No.: 10/799,576 Filed: March 12, 2004

Page : 10 of 19

59

Applicant: Tsann-Long Su et al. Serial No.: 10/799,576

Filed : March 12, 2004 Page : 11 of 19

52. (Currently amended) A pharmaceutical composition comprising a compound of formula (I) and a pharmaceutically acceptable carrier:

wherein.

each of R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, R<sub>8</sub>, R<sub>9</sub>, R<sub>10</sub>, R<sub>11</sub>, R<sub>12</sub>, and R<sub>13</sub> is, independently, hydrogen, halo, nitro, hydroxyl, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>1</sub>-C<sub>6</sub> hydroxyalkyl, CONHR<sup>a</sup>, NR<sup>b</sup>R<sup>e</sup>, CONH(CH<sub>2</sub>)<sub>m</sub>NR<sup>b</sup>R<sup>e</sup>, L-N(CH<sub>2</sub>CH<sub>2</sub>Cl)<sub>2</sub>, or a DNA minor groove binder;

L is  $(CH_2)_p$  or  $O(CH_2)_q$ ;

m is 1, 2, 3, or 4;

p is 0, 1, 2, 3, or 4;

q is 1, 2, 3, 4, 5, 6, 7, or 8;

in which,  $R^a$  is  $C_1$ - $C_6$  alkyl; each of  $R^b$  and  $R^c$  is, independently, hydrogen,  $C_1$ - $C_6$  alkyl,  $COR^d$ , or  $COOR^d$ ;  $R^d$  is  $C_1$ - $C_6$  alkyl,  $C_6$ - $C_{10}$  aryl, or  $C_7$ - $C_{12}$  aralkyl; provided that at least one of  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$ ,  $R_6$ ,  $R_7$ ,  $R_8$ ,  $R_9$ ,  $R_{10}$ ,  $R_{11}$ ,  $R_{12}$ , and  $R_{13}$  is L-N(CH<sub>2</sub>CH<sub>2</sub>Cl)<sub>2</sub>; or a pharmaceutically acceptable salt thereof.

Attorney's Docket No.: 08919-0118001

Applicant: Tsann-Long Su et al. Serial No.: 10/799,576 Filed: March 12, 2004

Page : 12 of 19

53. (Currently amended) A method of treating cancer, the method comprising administering to a subject in need thereof an effective amount of a compound of formula (I):

wherein,

each of R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, R<sub>8</sub>, R<sub>9</sub>, R<sub>10</sub>, R<sub>11</sub>, R<sub>12</sub>, and R<sub>13</sub> is, independently, hydrogen, halo, nitro, hydroxyl, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>1</sub>-C<sub>6</sub> hydroxyalkyl, CONHR<sup>a</sup>, NR<sup>b</sup>R<sup>c</sup>, CONH(CH<sub>2</sub>)<sub>m</sub>NR<sup>b</sup>R<sup>c</sup>, L-N(CH<sub>2</sub>CH<sub>2</sub>Cl)<sub>2</sub>, or a DNA minor groove binder;

L is (CH<sub>2</sub>)<sub>p</sub> or O(CH<sub>2</sub>)<sub>q</sub>; m is 1, 2, 3, or 4; p is 0, 1, 2, 3, or 4; q is 1, 2, 3, 4, 5, 6, 7, or 8;

in which,  $R^a$  is  $C_1$ - $C_6$  alkyl; each of  $R^b$  and  $R^c$  is, independently, hydrogen,  $C_1$ - $C_6$  alkyl,  $COR^d$ , or  $COOR^d$ ;  $R^d$  is  $C_1$ - $C_6$  alkyl,  $C_6$ - $C_{10}$  aryl, or  $C_7$ - $C_{12}$  aralkyl; and provided that at least one of  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$ ,  $R_6$ ,  $R_7$ ,  $R_8$ ,  $R_9$ ,  $R_{10}$ ,  $R_{11}$ ,  $R_{12}$ , and  $R_{13}$  is L-N(CH<sub>2</sub>CH<sub>2</sub>Cl)<sub>2</sub>; or a pharmaceutically acceptable salt thereof.